Press Releases

T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024. The products covered under the contract with Vizient include the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, which detect sepsis-causing bacterial and fungal pat

Ablaze Pharmaceuticals announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. to develop series of targeted radiopharmaceutical therapy products. Under the agreement. Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze from pharmaceutical research and preclinical activities to clinical studies. "This agreement with Yonghe represents a significant

Civil society organizations are hailing the expulsion of tobacco giant Philip Morris from Canada's major government-backed COVID-19 vaccine collaboration, Medicago Inc. Majority owner Mitsubishi Tanabe Pharma has removed Philip Morris as a secondary investor. The news follows the rejection of Medicago's Covifenz vaccine by the World Health Organization in March due to the corporation's tobacco industry ties. "Tobacco corporations, vaccines and governments don't

The U.S. Food and Drug Administration issued a Complete Response Letter  regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation in people living with fibrodysplasia ossificans progressiva. The CRL is related to the regulatory agency’s previous request for additional information on palovarotene clinical trial data communicated to Ipsen in October 2022, which is not a request for additional efficacy or safety

Hyphens Pharma International Limited  Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into exclusive license and supply agreements with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. for the exclusive rights to develop and commercialize Winlevi  cream 1% and all future product extension and/or improvement in the treatment of acne in 10 countries across Sout

Curadev  has created a Clinical Advisory Group comprising of eminent oncologists to provide guidance in the design and execution of immune-oncology clinical trials with CRD3874, its lead non nucleoside, allosteric small molecule STING agonist.  Curadev recently received permission from the US FDA to commence FIH trials with systemically administered CRD3874 in patients with advanced/metastatic solid cancers. Dr. Arjun Surya, CEO and CSO of Curadev said that, "We are honored to

POXEL SA a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis  and rare metabolic disorders, today announced the drawdown of the remaining two tranches of the convertible bonds as part of the equity-linked financing facility with Iris Capital Investment representing a total of EUR 2 million. Thomas Kuhn, Chief Executive Officer of Poxel, stated: “Fol

BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the companies provided approximately 11,500 doses of mRNA-based COVID-19 vaccines which arrived  on the Chinese Mainland on December 21, 2022. The delivery contains both the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine and the monovalent COVID-19 vaccine.   “We thank the Chinese and the German governments for their joint efforts and continuous support in helping us

Clearmind Medicine Inc. a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute. Similar patents have already been granted to Clearmind for the MEAI-based alcohol substitute in Europe and India. The development&ndas

BioNTech SE today announced that the first subject was dosed in a first-in-human Phase 1 clinical research study with BNT163, a herpes simplex virus vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1. The trial will evaluate the safety, tolerability, and immunogenicity of BNT163. The mRNA vaccine encodes three HSV-2 glycoproteins with the aim of helping to prevent HSV cellular entry and spread, as well as counteract the immunosuppressive properties o